Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

252.86 +0.43 (+0.17%)
Official Closing Price Updated: 6:30 PM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
ResMed (NYSE:RMD) Posts Better-Than-Expected Sales In Q4 But Stock Drops
Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its non-GAAP profit of $2.43 per share was 5.2% above... 
Via StockStory
In today's session, there are S&P500 stocks with remarkable trading volume.
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
Top S&P500 movers in Friday's session
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
ResMed Earnings Analysis: Q2 Recap
 
Via Benzinga
What 5 Analyst Ratings Have To Say About ResMed
 
Via Benzinga
Should you consider RESMED INC (NYSE:RMD) for quality investing?
RESMED INC (NYSE:RMD) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday?
Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings and positive macroeconomic data. The S&P 500 index stands... 
Via Benzinga
Topics Stocks
Friday's session: gap up and gap down stock in the S&P500 index
Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
ResMed: Digital Health Drives Q2 Growth
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability. 
Via The Motley Fool
Why Quality-Oriented Investors Should Consider NYSE:RMD.
Exploring RESMED INC (NYSE:RMD)'s quality characteristics. 
Via Chartmill
P/E Ratio Insights for ResMed
 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For ResMed
 
Via Benzinga
ResMed, In A Buy Zone, Stays Flat After Handily Beating Earnings Views
The company easily beat earnings expectations, while sales were narrowly above. 
Via Investor's Business Daily
Wall Street Remains Flat, Microsoft Eyes Heaviest Drop Since Late 2022, Gold Sets Fresh Records: What's Driving Markets Thursday?
Wall Street is struggling to find risk-on momentum, with major indexes stuck near the flatline at midday as investors assess the latest earnings reports from mega-cap tech stocks and... 
Via Benzinga
Reasonable Growth, Debt Levels, and a High ROIC Make RESMED INC (NYSE:RMD) Appealing to Quality Investors.
A fundamental analysis of (NYSE:RMD): Why Quality-Oriented Investors Should Consider NYSE:RMD. 
Via Chartmill
A Peek at ResMed's Future Earnings
 
Via Benzinga
Is RESMED INC (NYSE:RMD) suited for quality investing?
Analyzing the Quality Characteristics of RESMED INC (NYSE:RMD). 
Via Chartmill
Expert Outlook: ResMed Through The Eyes Of 7 Analysts
 
Via Benzinga
Earnings Scheduled For January 30, 2025
 
Via Benzinga
This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Top Stock Reports For UnitedHealth, Costco & IBM
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc., Costco Wholesale Corp., and International Business Machines Corp., as well as a micro-cap... 
Via Talk Markets
Topics Stocks / Equities
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. 
Via Investor's Business Daily
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth. 
Via Investor's Business Daily
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?
Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks. 
Via Benzinga
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
The major indexes were mixed for the week. 
Via Investor's Business Daily
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
ResMed reports Q1 2025 adjusted EPS of $2.20, up 34%, beating estimates. Revenue reached $1.22 billion, up 11%, driven by demand growth. 
Via Benzinga
My 3 Favorite Stocks to Buy Right Now
Here are three attractive stocks to buy that will give you a healthy mix of growth and dividends. 
Via The Motley Fool
Obesity Drugs-Tied ResMed Edges Higher On Quarterly Beat
The company beat fiscal first-quarter expectations. Shares are forming a flat base. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.